Drug Trial Radar · NCT04514419
Treatment of Breast Cancer With Trastuzumab + HS627/ Pertuzumab + Docetaxel
Last checked: Nov 19, 2026Latest source record: Nov 21, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
408
Planned (sponsor's estimate)
Start
Jun 28, 2020
Primary completion
Sep 11, 2024
Study completion Dec 2025
Sponsor
- Lead sponsor
- BioRay Pharmaceutical Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Aug 17, 2020
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Female only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The trial included screening period (4 weeks) and treatment period (4 treatment cycles, at least 12 weeks).
Conditions
- Breast Cancer
Interventions
HS627Drug
Prior to surgery: trastuzumab, HS627, and docetaxel for 4 cycles (1 cycle = 21 days).
PertuzumabDrug
Prior to surgery: trastuzumab, Pertuzumab, and docetaxel for 4 cycles (1 cycle = 21 days).
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of participants achieving Pathological Complete Response (pCR) as Assessed by the Independent Review Committee (IRC)Time frame: After surgery (At surgery cycle 4 Days 22-35)(1 cycle = 21 days)
Locations
1 site in 1 country. Site status is shown where the registry gives one.
The Affiliated Hospital of Qingdao University
Qingdao, Shandong, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.